Companies · Pharmaceuticals

Tosk Inc

Mountain View · Pharmaceuticals

Diligence memoA one-page analyst read on Tosk Inc — recommendation, valuation, rhythm, risks.
$8.6M
Total raised · real
3
Rounds
0.1×
Latest step-up
Top 50%
Sector rank · raised
Series A
Latest stage · inferred · Thu Sep 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Tosk Inc looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.8 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Tosk Inc is one of 1610 Pharmaceuticals companies tracked from Mountain View. By capital raised it ranks mid-pack (ahead of 51% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2022-09-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2011-12-16 Raised $798K (real) Modeled valuation $38M (est)Pre-Seed2011Seed · 2011-12-16 Raised $1.3M (real) Modeled valuation $50M (est)Seed2011Seed · 2011-12-16 Raised $1.7M (real) Modeled valuation $63M (est)Seed2011Series A · 2011-12-16 Raised $5.4M (real) Modeled valuation $169M (est)Series A2011Pre-Seed · 2016-03-23 Raised $766K (real) Modeled valuation $36M (est)Pre-Seed2016Series A · 2016-03-23 Raised $3.1M (real) Modeled valuation $96M (est)Series A2016Seed · 2016-03-23 Raised $1.5M (real) Modeled valuation $58M (est)Seed2016Series A · 2022-09-15 Raised $100K (real) Modeled valuation $1.2M (est)Series A2022+$1.3M+$1.7M+$5.4M+$766K+$3.1M+$1.5M+$100KCumulative $15M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$798K · 2011
Seed$1.3M · 2011
Seed extension$1.7M · 2011
Series A$5.4M · 2011
Bridge · Series A-stage$766K · 2016smaller follow-on
Series A extension$3.1M · 2016
Bridge · Series A-stage$1.5M · 2016smaller follow-on
Series A extension$100K · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.2M
Base estimate est.
$115K
Conservative case
$3.8M
Upside case
$455K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $37.7M · 2011-12-162011Seed · modeled $49.9M · 2011-12-16Seed · modeled $62.8M · 2011-12-16Series A · modeled $168.8M · 2011-12-16Pre-Seed · modeled $36.2M · 2016-03-23Series A · modeled $95.8M · 2016-03-23Seed · modeled $57.8M · 2016-03-23Series A · modeled $1.2M · 2022-09-152022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
3.8 yr
Elapsed time used
3.8 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
18 mo
Avg between rounds
$804K/yr
Capital velocity
14.5 yr
On record since
2011
First round
8
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$8.6M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$100K
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.2M
Sector median$76.1M

Raised more than 51% of sector peers (real $). Modeled value above 2% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #63 of 64.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Hallux, Inc. · Series A Raised $20.0M · modeled $151.4M (est)Enalare Therapeutics Inc. · Series A Raised $23.5M · modeled $150.7M (est)Silver Creek Pharmaceuticals, Inc. · Series A Raised $12.6M · modeled $139.1M (est)NQ PE Project Stingray Parent, L.P. · Series A Raised $11.4M · modeled $131.6M (est)Acta Pharmaceuticals, Inc. · Series A Raised $13.4M · modeled $121.3M (est)Groff North America, LLC · Series A Raised $13.1M · modeled $105.8M (est)Hoth Therapeutics, Inc. · Series A Raised $33.7M · modeled $100.5M (est)Eyegate Pharmaceuticals Inc · Series A Raised $72.9M · modeled $92.5M (est)resistanceBio, Inc. · Series A Raised $12.8M · modeled $79.4M (est)T3D Therapeutics, Inc. · Series A Raised $30.0M · modeled $70.8M (est)Aspire BioPharma, Inc. · Series A Raised $10.0M · modeled $69.4M (est)Octagon Therapeutics, Inc. · Series A Raised $12.4M · modeled $68.2M (est)Tosk Inc (this company) Raised $8.6M · modeled $1.2M (est)Tosk Inc
CompanyStageRaised · realValue · estvs peer med.
Hallux, Inc.Series A$20.0M$151.4M4.65×
Enalare Therapeutics Inc.Series A$23.5M$150.7M4.62×
Silver Creek Pharmaceuticals, Inc.Series A$12.6M$139.1M4.27×
NQ PE Project Stingray Parent, L.P.Series A$11.4M$131.6M4.04×
Acta Pharmaceuticals, Inc.Series A$13.4M$121.3M3.72×
Groff North America, LLCSeries A$13.1M$105.8M3.25×
Hoth Therapeutics, Inc.Series A$33.7M$100.5M3.08×
Eyegate Pharmaceuticals IncSeries A$72.9M$92.5M2.84×
resistanceBio, Inc.Series A$12.8M$79.4M2.44×
T3D Therapeutics, Inc.Series A$30.0M$70.8M2.17×
Aspire BioPharma, Inc.Series A$10.0M$69.4M2.13×
Octagon Therapeutics, Inc.Series A$12.4M$68.2M2.09×
Tosk Inc this companySeries A$8.6M$1.2M0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$798K2011-12-16$4.4M$37.7M85%
Seed$1.3M2011-12-16$6.6M$49.9M85%
Seed$1.7M2011-12-16$8.3M$62.8M85%
Series A$5.4M2011-12-16$24.8M$168.8M85%
Pre-Seed$766K2016-03-23$4.3M$36.2M90%
Series A$3.1M2016-03-23$14.1M$95.8M90%
Seed$1.5M2016-03-23$7.6M$57.8M90%
Series A$100K2022-09-15$455K$1.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$798K2011-12-16
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$1.3M2011-12-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× larger than the prior — scaling up.
    • 10 investors on this round.
  3. Seed$1.7M2011-12-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 12 investors on this round.
  4. Series A$5.4M2011-12-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.3× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 74 investors on this round.
  5. Pre-Seed$766K2016-03-23
    • Raised again after 51 mo — slower than the ~13 mo sector norm.
    • Round 7.1× smaller than the prior — bridge or down round.
    • 18 investors on this round.
  6. Series A$3.1M2016-03-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.0× larger than the prior — scaling up.
    • 56 investors on this round.
  7. Seed$1.5M2016-03-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 31 investors on this round.
  8. Series A$100K2022-09-15
    • Raised again after 78 mo — slower than the ~13 mo sector norm.
    • Round 15.2× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2024 ~Q1
Modeled next raise · ~18mo cadence
$100K
Modeled next size est.range $100K$160K
0.1×
Last step-up
$804K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Brian Frenzel2011-12
Charles Garvin2011-12
Harold Crow2011-12
Registry & provenance

Tosk Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1098412
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Insigna, Inc.PharmaceuticalsSeries A$8.5M$16.0Msame sector · same stage
AJNA BioSciences PBCPharmaceuticalsSeries A$9.0M$11.3Msame sector · same stage
Azora Therapeutics, Inc.PharmaceuticalsSeries A$8.3M$4.5Msame sector · same stage
DepYmed Inc.PharmaceuticalsSeries A$9.2M$910Ksame sector · same stage
Intezyne Technologies, Inc.PharmaceuticalsSeries A$9.3M$14.9Msame sector · same stage
Areva Pharmaceuticals Inc.PharmaceuticalsSeries A$8.0M$16.8Msame sector · same stage
Rose Pharmaceuticals, LLC.PharmaceuticalsSeries A$8.0M$16.8Msame sector · same stage
Aarvik Therapeutics, Inc.PharmaceuticalsSeries A$9.5M$5.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
LSK BioPartners, Inc.PharmaceuticalsSeries B$680.1M85%
Totusrx, Inc.PharmaceuticalsSeed$20.9M83%
Tocagen IncPharmaceuticalsSeries C$301.0M82%
JSK Therapeutics, Inc.PharmaPre-Seed$45.5M80%
FHKA Holdings LLCPharmaceuticalsPre-Seed$8.3M80%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.0M79%
Pharmaceutics International, Inc.PharmaceuticalsSeries D+$123.9M79%
Talphera, Inc.PharmaceuticalsSeries B$74.1M79%
Frequently asked
How much funding has Tosk Inc raised?
Tosk Inc has raised approximately $8.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Tosk Inc's estimated valuation?
Provath's modeled valuation for Tosk Inc is approximately $1.2M (modeled range $115K–$3.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Tosk Inc at?
Tosk Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Sep 15.
What does Tosk Inc do and where is it based?
Tosk Inc operates in the Pharmaceuticals sector, based in Mountain View.
Explore related

See where Tosk Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Tosk Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.